QuidelOrtho Corporation (QDEL)
NASDAQ: QDEL · Real-Time Price · USD
29.53
-0.37 (-1.24%)
At close: Jun 6, 2025, 4:00 PM
30.66
+1.13 (3.83%)
After-hours: Jun 6, 2025, 5:38 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2014 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 30, 2025 | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | 2014 - 2020 |
| Labs | 1.44B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Labs Growth | 2.22% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Point of Care | 678.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Point of Care Growth | -11.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Molecular Diagnostics | 24.40M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Molecular Diagnostics Growth | -11.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immunohematology | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immunohematology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Donor Screening | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Donor Screening Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Transfusion Medicine | 619.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Transfusion Medicine Growth | -5.18% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2014 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 30, 2025 | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | 2014 - 2020 |
| North America Adjusted EBITDA | 907.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Adjusted EBITDA Growth | 0.02% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Adjusted EBITDA | 50.20M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Adjusted EBITDA Growth | -19.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Adjusted EBITDA | 135.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Adjusted EBITDA Growth | 6.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Adjusted EBITDA | 131.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Adjusted EBITDA Growth | 4.05% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Adjusted EBITDA | -653.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Adjusted EBITDA Growth | 6.59% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2014 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 30, 2025 | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | 2014 - 2020 |
| North America | 1.59B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Growth | -7.85% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA | 339.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Growth | 2.75% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | 323.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | 2.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies | 508.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Growth | 4.14% |
Log In |
Log In |
Log In |
Log In | Upgrade
|